Synthetic receptors for logic gated T cell recognition and function

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Abramson, 2020, Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, Lancet, 396, 839, 10.1016/S0140-6736(20)31366-0 Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226 Nagarsheth, 2021, TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers, Nat Med, 27, 419, 10.1038/s41591-020-01225-1 D’Angelo, 2018, Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma, Cancer Discov, 8, 944, 10.1158/2159-8290.CD-17-1417 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol Ther, 18, 843, 10.1038/mt.2010.24 Srivastava, 2018, Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy, J Immunol, 200, 459, 10.4049/jimmunol.1701155 Srivastava, 2019, Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting, Cancer Cell, 35, 489, 10.1016/j.ccell.2019.02.003 Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020 Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547 Shah, 2020, CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial, J Clin Oncol, 38, 1938, 10.1200/JCO.19.03279 Samur, 2021, Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma, Nat Commun, 12, 10.1038/s41467-021-21177-5 Blank, 2019, Defining ‘T cell exhaustion’, Nat Rev Immunol, 19, 665, 10.1038/s41577-019-0221-9 Chen, 2019, NR4A transcription factors limit CAR T cell function in solid tumours, Nature, 567, 530, 10.1038/s41586-019-0985-x Sen, 2016, The epigenetic landscape of T cell exhaustion, Science, 354, 1165, 10.1126/science.aae0491 Martinez, 2019, CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment, Front Immunol, 10, 128, 10.3389/fimmu.2019.00128 Roybal, 2017, Synthetic immunology: hacking immune cells to expand their therapeutic capabilities, Annu Rev Immunol, 35, 229, 10.1146/annurev-immunol-051116-052302 Lim, 2017, The principles of engineering immune cells to treat cancer, Cell, 168, 724, 10.1016/j.cell.2017.01.016 Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat Biotechnol, 31, 71, 10.1038/nbt.2459 Fedorov, 2013, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci Transl Med, 5, 10.1126/scitranslmed.3006597 O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9, 10.1126/scitranslmed.aaa0984 Tchou, 2017, Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer, Cancer Immunol Res, 5, 1152, 10.1158/2326-6066.CIR-17-0189 Tran, 2016, T-cell transfer therapy targeting mutant KRAS in cancer, N Engl J Med, 375, 2255, 10.1056/NEJMoa1609279 Paulson, 2018, Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA, Nat Commun, 9, 10.1038/s41467-018-06300-3 Ahmadi, 2011, CD3 limits the efficacy of TCR gene therapy in vivo, Blood, 118, 3528, 10.1182/blood-2011-04-346338 van Loenen, 2010, Mixed T cell receptor dimers harbor potentially harmful neoreactivity, Proc Natl Acad Sci U S A, 107, 10972, 10.1073/pnas.1005802107 Zah, 2016, T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells, Cancer Immunol Res, 4, 498, 10.1158/2326-6066.CIR-15-0231 Hegde, 2016, Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape, J Clin Invest, 126, 3036, 10.1172/JCI83416 Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J Clin Invest, 126, 3814, 10.1172/JCI87366 de Larrea, 2020, Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma, Blood Cancer Discov, 1, 146, 10.1158/2643-3230.BCD-20-0020 Balakrishnan, 2019, Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors, Clin Cancer Res, 25, 7506, 10.1158/1078-0432.CCR-19-1479 Choi, 2019, CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity, Nat Biotechnol, 37, 1049, 10.1038/s41587-019-0192-1 Shah, 2020, Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial, Nat Med, 26, 1569, 10.1038/s41591-020-1081-3 Minutolo, 2019, The emergence of universal immune receptor T cell therapy for cancer, Front Oncol, 9, 176, 10.3389/fonc.2019.00176 Urbanska, 2012, A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor, Cancer Res, 72, 1844, 10.1158/0008-5472.CAN-11-3890 Lohmueller, 2017, mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting, Oncoimmunology, 7 Kudo, 2014, T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing, Cancer Res, 74, 93, 10.1158/0008-5472.CAN-13-1365 Rodgers, 2016, Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies, Proc Natl Acad Sci U S A, 113, E459, 10.1073/pnas.1524155113 Ma, 2016, Versatile strategy for controlling the specificity and activity of engineered T cells, Proc Natl Acad Sci U S A, 113, E450, 10.1073/pnas.1524193113 Tamada, 2012, Redirecting gene-modified T cells toward various cancer types using tagged antibodies, Clin Cancer Res, 18, 6436, 10.1158/1078-0432.CCR-12-1449 Dieckmann-Schuppert, 1993, Studies on O-glycans of Plasmodium-falciparum-infected human erythrocytes. Evidence for O-GlcNAc and O-GlcNAc-transferase in malaria parasites, Eur J Biochem, 216, 779, 10.1111/j.1432-1033.1993.tb18198.x Minutolo, 2020, Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor, J Am Chem Soc, 142, 6554, 10.1021/jacs.9b11622 Cho, 2018, Universal chimeric antigen receptors for multiplexed and logical control of T cell responses, Cell, 173, 1426, 10.1016/j.cell.2018.03.038 Wermke, 2021, Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML, Blood, 137, 3145, 10.1182/blood.2020009759 Lajoie, 2020, Designed protein logic to target cells with precise combinations of surface antigens, Science, 369, 1637, 10.1126/science.aba6527 Kopan, 2009, The canonical notch signaling pathway: unfolding the activation mechanism, Cell, 137, 216, 10.1016/j.cell.2009.03.045 Braune, 2016, Notch — a goldilocks signaling pathway in disease and cancer therapy, Discov Med, 21, 189 Morsut, 2016, Engineering customized cell sensing and response behaviors using synthetic notch receptors, Cell, 164, 780, 10.1016/j.cell.2016.01.012 Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011 Dannenfelser, 2020, Discriminatory power of combinatorial antigen recognition in cancer T cell therapies, Cell Syst, 11, 215, 10.1016/j.cels.2020.08.002 Choe, 2021, SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma, Sci Transl Med, 13, 10.1126/scitranslmed.abe7378 Williams, 2020, Precise T cell recognition programs designed by transcriptionally linking multiple receptors, Science, 370, 1099, 10.1126/science.abc6270 Hyrenius-Wittsten, 2021, SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models, Sci Transl Med, 13, 10.1126/scitranslmed.abd8836 Bonini, 1997, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science, 276, 1719, 10.1126/science.276.5319.1719 Hoyos, 2010, Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety, Leukemia, 24, 1160, 10.1038/leu.2010.75 Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N Engl J Med, 365, 1673, 10.1056/NEJMoa1106152 de Witte, 2008, An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease, J Immunol, 180, 6365, 10.4049/jimmunol.180.9.6365 Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360 Paszkiewicz, 2016, Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia, J Clin Invest, 126, 4262, 10.1172/JCI84813 Serafini, 2004, Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease, Hum Gene Ther, 15, 63, 10.1089/10430340460732463 Philip, 2014, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, 124, 1277, 10.1182/blood-2014-01-545020 Kieback, 2008, A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer, Proc Natl Acad Sci U S A, 105, 623, 10.1073/pnas.0710198105 Griffioen, 2008, Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application, Haematologica, 93, 1535, 10.3324/haematol.13067 Duong, 2019, Two-dimensional regulation of CAR-T cell therapy with orthogonal switches, Mol Ther Oncolytics, 12, 124, 10.1016/j.omto.2018.12.009 Wu, 2015, Remote control of therapeutic T cells through a small molecule-gated chimeric receptor, Science, 350, 10.1126/science.aab4077 Leung, 2019, Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization, JCI Insight, 5 Salzer, 2020, Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function, Nat Commun, 11, 10.1038/s41467-020-17970-3 Richman, 2020, Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo, Mol Ther, 28, 1600, 10.1016/j.ymthe.2020.06.004 Bonger, 2011, Small-molecule displacement of a cryptic degron causes conditional protein degradation, Nat Chem Biol, 7, 531, 10.1038/nchembio.598 Schade, 2008, Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation, Blood, 111, 1366, 10.1182/blood-2007-04-084814 Mestermann, 2019, The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells, Sci Transl Med, 11, 10.1126/scitranslmed.aau5907 Weber, 2019, Pharmacologic control of CAR-T cell function using dasatinib, Blood Adv, 3, 711, 10.1182/bloodadvances.2018028720 Weber, 2021, Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling, Science, 372, 10.1126/science.aba1786 Voisinne, 2019, Quantitative interactomics in primary T cells unveils TCR signal diversification extent and dynamics, Nat Immunol, 20, 1530, 10.1038/s41590-019-0489-8 Li, 2019, A comprehensive analysis of key immune checkpoint receptors on tumor-infiltrating T cells from multiple types of cancer, Front Oncol, 9, 1066, 10.3389/fonc.2019.01066 Demetriou, 2020, A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals, Nat Immunol, 21, 1232, 10.1038/s41590-020-0770-x Philip, 2019, Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections, Curr Opin Immunol, 58, 98, 10.1016/j.coi.2019.04.014 Langan, 2019, De novo design of bioactive protein switches, Nature, 572, 205, 10.1038/s41586-019-1432-8 Leaver-Fay, 2011, ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules, Methods Enzymol, 487, 545, 10.1016/B978-0-12-381270-4.00019-6